The following is a summary of "Comparison of first-line chemotherapy regimens in unresectable locally advanced or metastatic ...

Researchers have found an association between baseline circulating tumor cell count and survival in metastatic ...

Ratios of visceral proteins can act as independent indicators for both overall and progression-free survival in patients with ...

Patients in the induction chemotherapy group reported more frequent grade 3 or greater adverse events. Evidence Rating Level: ...

The combination of THIO and Libtayo has shown promising results among patients with advanced checkpoint inhibitor-resistant ...

A research team led by UCLA Health Jonsson Comprehensive Cancer Center investigators has shown that combining pembrolizumab, ...

The FDA recently approved the combination of inavolisib, fulvestrant, and palbociclib in this patient population.

The INAVO120 study reveals that the three-drug therapy inavolisib, palbociclib and fulvestrant significantly delays cancer ...

THURSDAY, Oct. 31, 2024 (HealthDay News) -- Inavolisib plus palbociclib-fulvestrant yields significantly longer ...

No significant difference was seen regarding progression-free survival between the tivozanib-nivolumab and tivozanib ...

Research and development (R&D) expenses: R&D expenses for the three months ended September 30, 2024, were $14.4 million, compared to $14.2 million for the same period in 2023. The increase was due ...